Altogether, even if data for ALK /ROS /RET translocations are preliminary and concern a low number of patients, we do not recommend ICI as single agents in patients with ALK/ROS1/RET rearranged NSCLC. This evidence concerns the gene ALK and non-small cell lung carcinoma.